Pharmacokinetic considerations for current state-of-the-art antidepressants

References

• Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299–2312.
   Google Scholar
• American Psychiatric Association. The diagnostic and statistical manual of mental disorders. 5th ed. DSM–5. American Psychiatric Publishing. 2013.
   Google Scholar
• Kraus C, Kadriu B, Lanzenberger R, et al. Prognosis and improved outcomes in major depression: a review. Transl Psychiatry. 2019;9:127.
   Google Scholar
• Gautam S, Jain A, Gautam M, et al. Clinical practice guidelines for the management of depression. Indian J Psychiatry. 2017;59:S34–S50.
   Google Scholar
• DeWilde KE, Levitch CF, Murrough JW, et al. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015;1345:47–58.
   Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–1366.
   Google Scholar
• 10 most-prescribed antidepressant medications | newsmax.com [Internet]. [ cited 2019 Jul 14]. Available from: https://www.newsmax.com/Health/Health-Wire/most-prescribed-antidepressant-medications/2015/09/02/id/673123/.
   Google Scholar
• Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Br J Psychiatry. 2000;177:292–302.
   Google Scholar
• Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49:1087–1206.
   Google Scholar
• Wille SMR, De Letter EA, Piette MHA, et al. Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry. Int J Legal Med. 2009;123:451–458.
   Google Scholar
• Schinkel. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 1999;36:179–194.
   Google Scholar
• O’Brien F, Clarke G, Fitzgerald P, et al. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. Br J Pharmacol. 2012;166:1333–1343.
   Google Scholar
• O’Brien FE, O’Connor RM, Clarke G, et al. The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram. Behav Brain Res. 2014;261:17–25.
   Google Scholar
• Ela AAE, Härtter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004;56:967–975.
   Google Scholar
• Feng B, Mills JB, Davidson RE, et al. In vitro p-glycoprotein assays to predict the in vivo interactions of p-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008;36:268–275.
   Google Scholar
• O’Brien FE, Dinan TG, Griffin BT, et al. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol. 2012;165:289–312.
   Google Scholar
• Doran A, Obach RS, Smith BJ, et al. The impact of P-glicoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/1b knockout mouse model. Drug Metab Dispos. 2004;33:165–174.
   Google Scholar
• Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d -tubocurarine. Clin Pharmacol Ther. 1979;25:358–371.
   Google Scholar
• Kreilgaard M, Smith DG, Brennum LT, et al. Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice. Br J Pharmacol. 2008;155:276–284.
   Google Scholar
• Erdo F. Microdialysis techniques in pharmacokinetic and biomarker studies past, present and future directions a review. Clin Exp Pharmacol. 2015;05.
   Google Scholar
• Budău M, Hancu G, Rusu A, et al. Chirality of modern antidepressants: an overview. Adv Pharm Bull. 2017;7:495–500.
   Google Scholar
• Fuller RW, Snoddy HD, Krushinski JH, et al. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology. 1992;31:997–1000.
   Google Scholar
• Fjordside L, Jeppesen U, Eap CB, et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics. 1999;9:55–60.
   Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006;31:122–131.
   Google Scholar
• Auclair AL, Martel JC, Assié MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338–347.
   Google Scholar
• Fritze S, Spanagel R, Noori HR. Adaptive dynamics of the 5-HT systems following chronic administration of selective serotonin reuptake inhibitors: a meta-analysis. J Neurochem. 2017;142:747–755.
   Google Scholar
• van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29:1–9.
   Google Scholar
• Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994;26:201–214.
   Google Scholar
• Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1997;32:1–21.
   Google Scholar
• van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993;24:203–220.
   Google Scholar
• Montgomery S. Serotonin noradrenaline reuptake inhibitors: logical evolution of antidepressant development. Int J Psychiatry Clin Pract. 2006;10:5–11.
   Google Scholar
• Knadler MP, Lobo E, Chappell J, et al. Duloxetine. Clin Pharmacokinet. 2011;50:281–294.
   Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657–665.
   Google Scholar
• Andrade C. Desvenlafaxine. Indian J Psychiatry. 2009;51:320–323.
   Google Scholar
• Coleman KA, Xavier VY, Palmer TL, et al. An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr. 2012;17:131–141.
   Google Scholar
• Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol. 1996;11(Suppl 4):15–27.
   Google Scholar
• Chen L, Greenberg WM, Gommoll C, et al. Levomilnacipran pharmacokinetics in healthy volunteers versus patients with major depressive disorder and implications for norepinephrine and serotonin reuptake inhibition. Clin Ther. 2015;37:2059–2070.
   Google Scholar
• Chen G, Højer A-M, Areberg J, et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57:673–686.
   Google Scholar
• Bundgaard C, Eneberg E, Sánchez C. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood–brain barrier in vivo. Neuropharmacology. 2016;103:104–111.
   Google Scholar
• Faquih AE, Memon RI, Hafeez H, et al. A review of novel antidepressants: a guide for clinicians. Cureus. 2019;11:e4185.
   Google Scholar
• Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs. 2009;18:1753–1764.
   Google Scholar
• Huecker MR, Smiley A, Saadabadi A. Bupropion. StatPearls Publishing; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470212/
   Google Scholar
• Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther. 2005;27:1685–1695.
   Google Scholar
• Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother. 2008;42:1822–1831.
   Google Scholar
• Fornaro M, Prestia D, Colicchio S, et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8:287–304.
   Google Scholar
• Timmer CJ, Ad Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38:461–474.
   Google Scholar
• Shami M, Elliott HL, Kelman AW, et al. The pharmacokinetics of mianserin. Br J Clin Pharmacol. 1983;15(Suppl 2):313S–322S.
   Google Scholar
• Eap CB, Lima CA, Macciardi F, et al. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. Ther Drug Monit. 1998;20:7–13.
   Google Scholar
• Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014;10:721–746.
   Google Scholar
• Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014;10:1457–1489.
   Google Scholar
• Boinpally R, Gad N, Gupta S, et al. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. Clin Ther. 2014;36:1638–1649.
   Google Scholar
• Chen G, Lee R, Højer A-M, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33:727–736.
   Google Scholar
• Chen L, Boinpally R, Gad N, et al. Evaluation of cytochrome P450 (CYP) 3A4-based interactions of levomilnacipran with ketoconazole, carbamazepine or alprazolam in healthy subjects. Clin Drug Investig. 2015;35:601–612.
   Google Scholar
• Yasui-Furukori N, Saito M, Niioka T, et al. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Ther Drug Monit. 2007;29:45–48.
   Google Scholar
• Jornil J, Jensen KG, Larsen F, et al. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010;38:376–385.
   Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13–37.
   Google Scholar
• Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 1996;11(Suppl 5):31–61.
   Google Scholar
• Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11–28.
   Google Scholar
• Bruno A, Morabito P, Spina E, et al. The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol. 2016;14:191–199.
   Google Scholar
• Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26:39–67.
   Google Scholar
• DeVane CL. Antidepressant–drug interactions are potentially but rarely clinically significant. Neuropsychopharmacology. 2006;31:1594–1604.
   Google Scholar
• Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12:601–610.
   Google Scholar
• Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67–76.
   Google Scholar
• Boyce RD, Handler SM, Karp JF, et al. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother. 2012;10:139–150.
   Google Scholar
• DeVane CL, Pollock BG. Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry. 1999;60(Suppl 20):38–44.
   Google Scholar
• Ferguson JM, Hill H. Pharmacokinetics of fluoxetine in elderly men and women. Gerontology. 2006;52:45–50.
   Google Scholar
• EMA. Valdoxan, INN-agomelatine - European Medicines Agency - Europa. Annex i. Summary of product characteristics. 2009.
   Google Scholar
• Sproule AB, Hazra M, Pollock GB. Desvenlafaxine succinate for major depressive disorder. Drugs Today. 2008;44:475.
   Google Scholar
• Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol. 1995;35:876–884.
   Google Scholar
• EMA. Brintellix, INN-vortioxetine - Europa. Annex i. Summary od product characteristics. 2013.
   Google Scholar
• Choi E, Zmarlicka M, Ehret MJ. Vilazodone: A novel antidepressant. Am J Health Syst Pharm. 2012;69:1551–1557.
   Google Scholar
• Allergan Inc. FETZIMA® Product Monograph. 2010.
   Google Scholar
• Lužný J. Agomelatine in elderly–finally a patient friendly antidepressant in psychogeriatry? Actas Esp Psiquiatr. 2012;40:304–307.
   Google Scholar
• Heun R, Ahokas A, Boyer P, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder. J Clin Psychiatry. 2013;74:587–594.
   Google Scholar
• Truijens SEM, Spek V, van Son MJM, et al. Different patterns of depressive symptoms during pregnancy. Arch Womens Ment Health. 2017;20:539–546.
   Google Scholar
• Pearlstein T, Howard M, Salisbury A, et al. Postpartum depression. Am J Obstet Gynecol. 2009;200:357–364.
   Google Scholar
• Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90:288–291.
   Google Scholar
• Paulzen M, Goecke TW, Stickeler E, et al. Sertraline in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. J Affect Disord. 2017;212:1–6.
   Google Scholar
• Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42:95–100.
   Google Scholar
• Fokina VM, West H, Oncken C, et al. Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. Am J Obstet Gynecol. 2016;215:497.e1–7.
   Google Scholar
• Berle JØ, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011;7:28–34.
   Google Scholar
• Di Scalea TL, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol. 2009;52:483–497.
   Google Scholar
• Kim J, Riggs KW, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 2006;61:155–163.
   Google Scholar
• Kristensen JH, Ilett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol. 1999;48:521–527.
   Google Scholar
• Spigset O, Carieborg L, Ohman R, et al. Excretion of citalopram in breast milk. Br J Clin Pharmacol. 1997;44:295–298.
   Google Scholar
• Schenker S, Bergstrom RF, Wolen RL, et al. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1988;44:353–359.
   Google Scholar
• Mullish BH, Kabir MS, Thursz MR, et al. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther. 2014;40:880–892.
   Google Scholar
• Boinpally R, Henry D, Gupta S, et al. Pharmacokinetics and safety of vilazodone in hepatic impairment. Am J Ther. 2015;22:269–277.
   Google Scholar
• Chen L, Boinpally R, Greenberg WM, et al. Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants. Clin Drug Investig. 2014;34:351–359.
   Google Scholar
• Hedayati SS, Yalamanchili V, Finkelstein FO. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney Int. 2012;81:247–255.
   Google Scholar
• Nagler EV, Webster AC, Vanholder R, et al. Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European renal best practice (ERBP)*. Nephrol Dial Transplant. 2012;27:3736–3745.
   Google Scholar
• Levy NB, Blumenfield M, Beasley CM, et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatry. 1996;18:8–13.
   Google Scholar
• Turpeinen M, Koivuviita N, Tolonen A, et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol. 2007;64:165–173.
   Google Scholar
• Chen L, Greenberg W, Brand-Schieber E, et al. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. Drug Des Devel Ther. 2015;9:3293.
   Google Scholar
• Boinpally R, Alcorn H, Adams MH, et al. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. Clin Drug Investig. 2013;33:199–206.
   Google Scholar
• Chen G, Nomikos GG, Affinito J, et al. Effects of intrinsic factors on the clinical pharmacokinetics of vortioxetine. Clin Pharmacol Drug Dev. 2018;7:880–888.
   Google Scholar
• Müller MJ, Dragicevic A, Fric M, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36:98–104.
   Google Scholar
• Sakolsky DJ, Perel JM, Emslie GJ, et al. Antidepressant exposure as a predictor of clinical outcomes in the treatment of resistant depression in adolescents (TORDIA) study. J Clin Psychopharmacol. 2011;31:92–97.
   Google Scholar
• Norman TR, Gupta RK, Burrows GD, et al. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol. 1993;8:25–29.
   Google Scholar
• Kasper S, Dötsch M, Kick H, et al. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol. 1993;3:13–21.
   Google Scholar
• Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000;22:143–154.
   Google Scholar
• Hiemke C, Bergemann N, Clement H, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
   Google Scholar
• Ostad Haji E, Hiemke C, Pfuhlmann B. Therapeutic drug monitoring for antidepressant drug treatment. Curr Pharm Des. 2012;18:5818–5827.
   Google Scholar
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19:69–76.
   Google Scholar
• Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet. 1995;29:192–209.
   Google Scholar
• Petrović J, Pešić V, Lauschke VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet. 2019 Jul 29. doi: 10.1038/s41431-019-0480-8.
   Google Scholar
• Hicks J, Bishop J, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127–134.
   Google Scholar
• Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin*. Clin Pharmacol Ther. 1996;60:512–521.
   Google Scholar
• Scordo MG, Spina E, Dahl M-L, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005;97:296–301.
   Google Scholar
• Nichols AI, Focht K, Jiang Q, et al. Pharmacokinetics of venlafaxine extended release 75mg and desvenlafaxine 50mg in healthy CYP2D6 extensive and poor metabolizers: A randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig. 2011;31:155–167.
   Google Scholar
• Jukić MM, Haslemo T, Molden E, et al. Impact of cyp2c19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry. 2018;175:463–470.
   Google Scholar
• Yu B-N, Chen G-L, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos. 2003;31:1255–1259.
   Google Scholar
• Areberg J, Petersen KB, Chen G, et al. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol. 2014;115:552–559.
   Google Scholar
• Preskorn SH, Kane CP, Lobello K, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression. J Clin Psychiatry. 2013;74:614–621.
   Google Scholar
• Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9:819–825.
   Google Scholar
• Martin J, Lee KC. Pharmacogenomics of antidepressants for major depressive disorder. Ment Health Clin. 2012;1:222–224.
   Google Scholar
• Kumar Y, Kung S, Shinozaki G. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. J Psychopharmacol. 2014;28:1143–1148.
   Google Scholar
• Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37–44.
   Google Scholar
• Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173–192.
   Google Scholar
• Kirchheiner J, Seeringer A, Viviani R. Pharmacogenetics in psychiatry - a useful clinical tool or wishful thinking for the future? Curr Pharm Des. 2010;16:136–144.
   Google Scholar
• Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12:247–257.
   Google Scholar
• McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804–814.
   Google Scholar
• Uher R, Tansey KE, Henigsberg N, et al. Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170:207–217.
   Google Scholar
• Health Quality Ontario HQ. Pharmacogenomic testing for psychotropic medication selection: a systematic review of the assurex genesight psychotropic test. Ont Health Technol Assess Ser. 2017;17:1–39.
   Google Scholar